Red Biotechnology Market Synopsis

Red Biotechnology Market Size Was Valued at USD 570.2 Billion in 2023, and is Projected to Reach USD 1412.0 Billion by 2032, Growing at a CAGR of  10.60% From 2024-2032.

Red biotechnology is the biotechnological practice that aims at designing and manufacturing of biotechnological products and services in the medical and healthcare sector for diagnostic, therapeutic and preventive purposes. This segment contains something from the creation of an innovative medicine, vaccines, gene therapies and tissue engineering. Red biotechnology applies living organisms, cells and bio systems to develop drugs that can manage various diseases, and offer better patient care and optimum health solutions. With the development of the research field, the red biotechnology not only is continuously involved in the development of personalized medicine and regenerative medicine, but also has significant changes in the overall development of modern medical care.

• It is worth noting, that red biotechnology market is one of the most active and constantly changing segments of overall biotechnology industry, with stronger emphasis on healthcare and medical field. It covers virtually all types of goods and services and extends from biopharmaceuticals to gene therapy to regenerative medicine. The growth in this sector can further be attributed to factors like demographic change, especially aging population, emergent diseases, biotechnological research and development. Also, the increasing development of individualized medicine and targeted therapy will put pressure on the change of key driving forces such as the development of advanced biotechnological options in order to enhance the functioning of the entire system.
• Regionally, North America takes up the largest share of the red biotechnology market thanks to its well-developed healthcare industry, increased funding toward research and development, and favourable policies. Nonetheless, the Asia-Pacific region seems to be coming into focus due to increase potential investment towards biotechnology, growing health care expenditure and innovation partnership between university and industry. In the future as the markets grow more competitive, the major activities such as forming of alliances, acquisitions and mergers, and embracing of new technologies will be core determinants for organizations to achieve competitive advantages. The adoption of artificial intelligence and machine learning in the process of biopharmaceutical development will also improve productivity in this industry, and reduce the time it takes to launch new therapeutics.
• Issues like regulatory structures, expensive development of the product, and some issues of ethical consideration in the genetic area may slow its market growth. However, the red biotechnology market is set to experience great growth in the years to come, primarily driven by innovation, robust R&D, and collaboration in the global biotechnology system. Given that companies want to provide improved and safer therapeutic approaches, need for red biotechnology solutions is expected to grow subsequently enhancing the quality of life for the patient globally.

Red Biotechnology Market Trend Analysis

The Rise of Personalized Medicine in the Red Biotechnology Market

• Another trend that has been recorded for the red biotechnology market presents personalized medicine, which is based on an individual genotype. This change is highly driven by the growth of the genomic and proteomic technologies that can enable the operationalization of individualized treatment plans that are tailored for patient physical characteristics. With genomic sequencing and analysis, the clinician discovers genetic mutation and variation that results to disease promoting specific diagnosis and therapy. Hence, the biotechnology companies are directing more capital in the research and development in order to develop new therapeutic solutions for the chronic diseases such as Cancer, diabetes and genetic disorders. It does not only improves the quality of treatment, but also reduces potential harm, which is beneficial for doctor-patient relationship.
• There is increasing concern with precision medicine which presents a strong growth incentive to the red biotechnology market as patients demand better options. The above trend is part of a larger trend in ‘ precision medicine, ’ where care delivery is not standardized but molecular and genetic particularities are taken into account. Increased patient awareness regarding their diseases and the possibility of customized treatments means that the latter will be demanded by the former. Therefore, there is an interest in increasing portfolio of biotechnology companies by offering broad-spectrum customized deposits to meet the market demands. It is important to underline that this trend is not only changing the whole picture of the red biotechnology landscape but also is creating conditions for new brilliant ideas that can become a basis for providing the higher level of patient’s treatment and the quality of life.

Growing Focus on Biopharmaceuticals in the Red Biotechnology Market

• One more noticeable ongoing tendency influencing the character of the red biotechnology market pertains to the preservation of the trend towards biopharmaceuticals, with paramount regard to the proteins and antibodies and the vaccines, in particular. Continued needs for therapy and prevention of different diseases, especially new and re-emerging communicable diseases, have driven the growth of the biopharmaceutical field. The emergence of COVID-19 also plays a crucial role in underlining the relevance of biotechnology as a sector that could develop the vaccines quickly and with fewer resources needed than any other sector. Based on such experience, governments as well as private parties have increased investment in biopharmaceutical R & D in view of the fact that advancement in research is key to improving health standards across the world. Such an increase in investment should help spur the development of new and improved treatments and vaccines to strengthen the market’s growth trend.
• Moreover, the advancement of biosimilar production is shaking the red biotechnology environment as an affordable option to classical biologics. These products are very much similar to approved reference biologics, however they are most often cheaper and therefore more available for patients.. Why biosimilars are important is especially helpful in an era where cost pressures continue to weigh on the system and where there is growing need for access to cheaper drugs. Because health care consumers and practitioners are ever in search of the cheaper drugs, the increased access created by biosimilars will enhance patient compliance to treatment regimens. This trend doesn’t only help the economic dimension of healthcare but also contributes to have a more sustainable bio-pharmaceutical industry that deliver the required treatments without exorbitant costs.

Red Biotechnology Market Segment Analysis:

Red Biotechnology Market Segmented based on By Product and By End User

By Product, Monoclonal Antibodies segment is expected to dominate the market during the forecast period

• mAbs are well established in the modern medicine and oncology in particular, as well as in the treatment of autoimmune diseases. These engineered antibodies are made to latch themselves onto antigens present on the surface of cells, for a therapeutic approach that reduces the injury of adjacent cells. It is a fact that this specificity does not only improve the effectiveness of the treatments in comparison to those conventional methods but also minimizes side effects. Personalised medicine involves using drugs or treatments that are specific to an individual with respect to their genetic and molecular characterisation and the idea of using monoclonal antibodies that can be produced coded for individual patients figures prominently in the new order. As a result of it, the use of such techniques is not limited to oncological practice and autoimmunity treatment but also infectology and cardiovascular disease as well, which expands their scope in medicine.
• There is a significant growth in the demand for monoclonal antibodies informed by some factors as explained below. An increase in the incidence of chronic pathology, including malignant neoplasms of various localization and autoimmune reactions, creates a demand for appropriate therapy. Furthermore, the techniques in bio technology have been improved to develop processes in monoclonal antibodies with higher gains in productivity at lesser costs. Given the current advances in monoclonal antibodies as antigens and growing research efforts in seeking new molecular targets for treatment as well as improving specificity and implications of these antibodies, monoclonal antibodies’ market has great prospects. This trend is also discovered from measures spent on research and development by both pharmaceutical industries and academic organizations pointing to the fact that Monoclonal antibodies will be critical in future therapeutic plans.

By End User, Academic Research Institutes segment held the largest share in 2023

• An appreciable number of academic research institutes also have a significant role in the shape of the biopharmaceutical industry since they act as stimulators and research centers. These are centres of research where, tapping a broad and complex suite of biopharmaceutical tools, including monoclonal antibody reagents, recombinant proteins and gene therapies, investigators seek to make methodological breakthroughs. The work that they do not only contributes to an increased comprehension of a number of regulatory constructs in biological systems, but it also provides the basis for constructing novel forms of treatment and of medicine. In concert with advance industries and by seeking grant money from the federal and private sectors, academic research can expand uncharted frontiers for further health care advancement.
• In addition to basic science, academic research institutes are now conducting translational research which clinical application to human diseases. Through preclinical research and clinical research, these institutions are useful in determining the effectiveness and safety profile of novel biopharmaceutical products. Many of their conclusions are used to develop regulation policies and to predict further tendencies in biopharmaceutical industry. Thus, a mutual cooperation of academic research and the Biopharmaceutical industry is both enhancing the speed of scientific progression and creating a culture for innovation which aims at enhancing preferred patient benefits and tackling emerging healthcare needs.

Red Biotechnology Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• In North America especially in United States the red biotechnology market is backed by sound health facility that enhances various development specialty medical treatment. It has become the breeding ground for established players in the biopharmaceutical field, as well as leading research organizations. A large investment in research and development is essential to achieve innovation specifically in the field of regenerative medicine and gene therapy. The occurrence of chronic diseases of diabetes, cancer, cardiovascular diseases and many others make it important to look for other treatment mechanism which can be found under Red Biotechnology hence enhancing its growth in the region.
• Furthermore, approval from the U.S Food and Drug authority such as the FDA has a highly significant role by supporting the acceleration of the approval process of the products of the Biotechnology industry. As well as benefiting investors and developers, this support also helps to achieve patient timely access to new treatments. Encouraging development and innovation by the FDA and a comparatively short time that is needed to pass through all the necessary stages of regulation provides opportunities for translating the results of research into efficient and practical applications in the practice of medicine. Therefore, North America is still retaining its position in the global red biotechnology market due to the continued synergy of stakeholder, which include the academia, industry and the regulatory entitiess, to foster the market development and enhance the wellbeing of the populace.

Active Key Players in the Red Biotechnology Market

• Merck KGaA
• F. Hoffmann-La Roche AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• AstraZeneca Plc
• Takeda Pharmaceutical Company Limited
• Gilead Sciences
• Biogen Inc.
• Amgen Inc.
• Celgene Corporation
• Other Key Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Red Biotechnology Market by Product
 4.1 Red Biotechnology Market Snapshot and Growth Engine
 4.2 Red Biotechnology Market Overview
 4.3 Monoclonal Antibodies
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Monoclonal Antibodies: Geographic Segmentation Analysis
 4.4 Polyclonal Antibodies
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Polyclonal Antibodies: Geographic Segmentation Analysis
 4.5 Recombinant Proteins
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Recombinant Proteins: Geographic Segmentation Analysis
 4.6 Vaccines
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Vaccines: Geographic Segmentation Analysis
 4.7 Cell-Based Immunotherapy Products
  4.7.1 Introduction and Market Overview
  4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.7.3 Key Market Trends, Growth Factors and Opportunities
  4.7.4 Cell-Based Immunotherapy Products: Geographic Segmentation Analysis
 4.8 Gene Therapy Products
  4.8.1 Introduction and Market Overview
  4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.8.3 Key Market Trends, Growth Factors and Opportunities
  4.8.4 Gene Therapy Products: Geographic Segmentation Analysis
 4.9 Cell Therapy Products
  4.9.1 Introduction and Market Overview
  4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.9.3 Key Market Trends, Growth Factors and Opportunities
  4.9.4 Cell Therapy Products: Geographic Segmentation Analysis
 4.10 Tissue-Engineered Products
  4.10.1 Introduction and Market Overview
  4.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.10.3 Key Market Trends, Growth Factors and Opportunities
  4.10.4 Tissue-Engineered Products: Geographic Segmentation Analysis
 4.11 Stem Cells
  4.11.1 Introduction and Market Overview
  4.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.11.3 Key Market Trends, Growth Factors and Opportunities
  4.11.4 Stem Cells: Geographic Segmentation Analysis
 4.12 Cell Culture
  4.12.1 Introduction and Market Overview
  4.12.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.12.3 Key Market Trends, Growth Factors and Opportunities
  4.12.4 Cell Culture: Geographic Segmentation Analysis
 4.13 Viral Vector
  4.13.1 Introduction and Market Overview
  4.13.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.13.3 Key Market Trends, Growth Factors and Opportunities
  4.13.4 Viral Vector: Geographic Segmentation Analysis
 4.14 Enzymes
  4.14.1 Introduction and Market Overview
  4.14.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.14.3 Key Market Trends, Growth Factors and Opportunities
  4.14.4 Enzymes: Geographic Segmentation Analysis
 4.15 Kits and Reagents
  4.15.1 Introduction and Market Overview
  4.15.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.15.3 Key Market Trends, Growth Factors and Opportunities
  4.15.4 Kits and Reagents: Geographic Segmentation Analysis
 4.16 Animal models
  4.16.1 Introduction and Market Overview
  4.16.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.16.3 Key Market Trends, Growth Factors and Opportunities
  4.16.4 Animal models: Geographic Segmentation Analysis
 4.17 Molecular diagnostics
  4.17.1 Introduction and Market Overview
  4.17.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.17.3 Key Market Trends, Growth Factors and Opportunities
  4.17.4 Molecular diagnostics: Geographic Segmentation Analysis

Chapter 5: Red Biotechnology Market by By End User
 5.1 Red Biotechnology Market Snapshot and Growth Engine
 5.2 Red Biotechnology Market Overview
 5.3 Academic Research Institutes
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Academic Research Institutes: Geographic Segmentation Analysis
 5.4 CMOs & CROs
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 CMOs & CROs: Geographic Segmentation Analysis
 5.5 Pharmaceutical & Biotechnology Companies
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Pharmaceutical & Biotechnology Companies: Geographic Segmentation Analysis

Chapter 6: Company Profiles and Competitive Analysis
 6.1 Competitive Landscape
  6.1.1 Competitive Benchmarking
  6.1.2 Red Biotechnology Market Share by Manufacturer (2023)
  6.1.3 Industry BCG Matrix
  6.1.4 Heat Map Analysis
  6.1.5 Mergers and Acquisitions
  
 6.2 MERCK KGAA
  6.2.1 Company Overview
  6.2.2 Key Executives
  6.2.3 Company Snapshot
  6.2.4 Role of the Company in the Market
  6.2.5 Sustainability and Social Responsibility
  6.2.6 Operating Business Segments
  6.2.7 Product Portfolio
  6.2.8 Business Performance
  6.2.9 Key Strategic Moves and Recent Developments
  6.2.10 SWOT Analysis
 6.3 F HOFFMANN-LA ROCHE AG
 6.4 PFIZER INC
 6.5 REGENERON PHARMACEUTICALS INC
 6.6 ASTRAZENECA PLC
 6.7 TAKEDA PHARMACEUTICAL COMPANY LIMITED
 6.8 GILEAD SCIENCES
 6.9 BIOGEN INC
 6.10 AMGEN INC
 6.11 CELGENE CORPORATION
 6.12 OTHER ACTIVE PLAYERS

Chapter 7: Global Red Biotechnology Market By Region
 7.1 Overview
 7.2. North America Red Biotechnology Market
  7.2.1 Key Market Trends, Growth Factors and Opportunities
  7.2.2 Top Key Companies
  7.2.3 Historic and Forecasted Market Size by Segments
  7.2.4 Historic and Forecasted Market Size By Product
  7.2.4.1 Monoclonal Antibodies
  7.2.4.2 Polyclonal Antibodies
  7.2.4.3 Recombinant Proteins
  7.2.4.4 Vaccines
  7.2.4.5 Cell-Based Immunotherapy Products
  7.2.4.6 Gene Therapy Products
  7.2.4.7 Cell Therapy Products
  7.2.4.8 Tissue-Engineered Products
  7.2.4.9 Stem Cells
  7.2.4.10 Cell Culture
  7.2.4.11 Viral Vector
  7.2.4.12 Enzymes
  7.2.4.13 Kits and Reagents
  7.2.4.14 Animal models
  7.2.4.15 Molecular diagnostics
  7.2.5 Historic and Forecasted Market Size By By End User
  7.2.5.1 Academic Research Institutes
  7.2.5.2 CMOs & CROs
  7.2.5.3 Pharmaceutical & Biotechnology Companies
  7.2.6 Historic and Forecast Market Size by Country
  7.2.6.1 US
  7.2.6.2 Canada
  7.2.6.3 Mexico
 7.3. Eastern Europe Red Biotechnology Market
  7.3.1 Key Market Trends, Growth Factors and Opportunities
  7.3.2 Top Key Companies
  7.3.3 Historic and Forecasted Market Size by Segments
  7.3.4 Historic and Forecasted Market Size By Product
  7.3.4.1 Monoclonal Antibodies
  7.3.4.2 Polyclonal Antibodies
  7.3.4.3 Recombinant Proteins
  7.3.4.4 Vaccines
  7.3.4.5 Cell-Based Immunotherapy Products
  7.3.4.6 Gene Therapy Products
  7.3.4.7 Cell Therapy Products
  7.3.4.8 Tissue-Engineered Products
  7.3.4.9 Stem Cells
  7.3.4.10 Cell Culture
  7.3.4.11 Viral Vector
  7.3.4.12 Enzymes
  7.3.4.13 Kits and Reagents
  7.3.4.14 Animal models
  7.3.4.15 Molecular diagnostics
  7.3.5 Historic and Forecasted Market Size By By End User
  7.3.5.1 Academic Research Institutes
  7.3.5.2 CMOs & CROs
  7.3.5.3 Pharmaceutical & Biotechnology Companies
  7.3.6 Historic and Forecast Market Size by Country
  7.3.6.1 Bulgaria
  7.3.6.2 The Czech Republic
  7.3.6.3 Hungary
  7.3.6.4 Poland
  7.3.6.5 Romania
  7.3.6.6 Rest of Eastern Europe
 7.4. Western Europe Red Biotechnology Market
  7.4.1 Key Market Trends, Growth Factors and Opportunities
  7.4.2 Top Key Companies
  7.4.3 Historic and Forecasted Market Size by Segments
  7.4.4 Historic and Forecasted Market Size By Product
  7.4.4.1 Monoclonal Antibodies
  7.4.4.2 Polyclonal Antibodies
  7.4.4.3 Recombinant Proteins
  7.4.4.4 Vaccines
  7.4.4.5 Cell-Based Immunotherapy Products
  7.4.4.6 Gene Therapy Products
  7.4.4.7 Cell Therapy Products
  7.4.4.8 Tissue-Engineered Products
  7.4.4.9 Stem Cells
  7.4.4.10 Cell Culture
  7.4.4.11 Viral Vector
  7.4.4.12 Enzymes
  7.4.4.13 Kits and Reagents
  7.4.4.14 Animal models
  7.4.4.15 Molecular diagnostics
  7.4.5 Historic and Forecasted Market Size By By End User
  7.4.5.1 Academic Research Institutes
  7.4.5.2 CMOs & CROs
  7.4.5.3 Pharmaceutical & Biotechnology Companies
  7.4.6 Historic and Forecast Market Size by Country
  7.4.6.1 Germany
  7.4.6.2 UK
  7.4.6.3 France
  7.4.6.4 Netherlands
  7.4.6.5 Italy
  7.4.6.6 Russia
  7.4.6.7 Spain
  7.4.6.8 Rest of Western Europe
 7.5. Asia Pacific Red Biotechnology Market
  7.5.1 Key Market Trends, Growth Factors and Opportunities
  7.5.2 Top Key Companies
  7.5.3 Historic and Forecasted Market Size by Segments
  7.5.4 Historic and Forecasted Market Size By Product
  7.5.4.1 Monoclonal Antibodies
  7.5.4.2 Polyclonal Antibodies
  7.5.4.3 Recombinant Proteins
  7.5.4.4 Vaccines
  7.5.4.5 Cell-Based Immunotherapy Products
  7.5.4.6 Gene Therapy Products
  7.5.4.7 Cell Therapy Products
  7.5.4.8 Tissue-Engineered Products
  7.5.4.9 Stem Cells
  7.5.4.10 Cell Culture
  7.5.4.11 Viral Vector
  7.5.4.12 Enzymes
  7.5.4.13 Kits and Reagents
  7.5.4.14 Animal models
  7.5.4.15 Molecular diagnostics
  7.5.5 Historic and Forecasted Market Size By By End User
  7.5.5.1 Academic Research Institutes
  7.5.5.2 CMOs & CROs
  7.5.5.3 Pharmaceutical & Biotechnology Companies
  7.5.6 Historic and Forecast Market Size by Country
  7.5.6.1 China
  7.5.6.2 India
  7.5.6.3 Japan
  7.5.6.4 South Korea
  7.5.6.5 Malaysia
  7.5.6.6 Thailand
  7.5.6.7 Vietnam
  7.5.6.8 The Philippines
  7.5.6.9 Australia
  7.5.6.10 New Zealand
  7.5.6.11 Rest of APAC
 7.6. Middle East & Africa Red Biotechnology Market
  7.6.1 Key Market Trends, Growth Factors and Opportunities
  7.6.2 Top Key Companies
  7.6.3 Historic and Forecasted Market Size by Segments
  7.6.4 Historic and Forecasted Market Size By Product
  7.6.4.1 Monoclonal Antibodies
  7.6.4.2 Polyclonal Antibodies
  7.6.4.3 Recombinant Proteins
  7.6.4.4 Vaccines
  7.6.4.5 Cell-Based Immunotherapy Products
  7.6.4.6 Gene Therapy Products
  7.6.4.7 Cell Therapy Products
  7.6.4.8 Tissue-Engineered Products
  7.6.4.9 Stem Cells
  7.6.4.10 Cell Culture
  7.6.4.11 Viral Vector
  7.6.4.12 Enzymes
  7.6.4.13 Kits and Reagents
  7.6.4.14 Animal models
  7.6.4.15 Molecular diagnostics
  7.6.5 Historic and Forecasted Market Size By By End User
  7.6.5.1 Academic Research Institutes
  7.6.5.2 CMOs & CROs
  7.6.5.3 Pharmaceutical & Biotechnology Companies
  7.6.6 Historic and Forecast Market Size by Country
  7.6.6.1 Turkey
  7.6.6.2 Bahrain
  7.6.6.3 Kuwait
  7.6.6.4 Saudi Arabia
  7.6.6.5 Qatar
  7.6.6.6 UAE
  7.6.6.7 Israel
  7.6.6.8 South Africa
 7.7. South America Red Biotechnology Market
  7.7.1 Key Market Trends, Growth Factors and Opportunities
  7.7.2 Top Key Companies
  7.7.3 Historic and Forecasted Market Size by Segments
  7.7.4 Historic and Forecasted Market Size By Product
  7.7.4.1 Monoclonal Antibodies
  7.7.4.2 Polyclonal Antibodies
  7.7.4.3 Recombinant Proteins
  7.7.4.4 Vaccines
  7.7.4.5 Cell-Based Immunotherapy Products
  7.7.4.6 Gene Therapy Products
  7.7.4.7 Cell Therapy Products
  7.7.4.8 Tissue-Engineered Products
  7.7.4.9 Stem Cells
  7.7.4.10 Cell Culture
  7.7.4.11 Viral Vector
  7.7.4.12 Enzymes
  7.7.4.13 Kits and Reagents
  7.7.4.14 Animal models
  7.7.4.15 Molecular diagnostics
  7.7.5 Historic and Forecasted Market Size By By End User
  7.7.5.1 Academic Research Institutes
  7.7.5.2 CMOs & CROs
  7.7.5.3 Pharmaceutical & Biotechnology Companies
  7.7.6 Historic and Forecast Market Size by Country
  7.7.6.1 Brazil
  7.7.6.2 Argentina
  7.7.6.3 Rest of SA

Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies

Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research